Enliven Therapeutics Files 8-K
Ticker: ELVN · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Enliven Therapeutics (formerly IMARA) filed an 8-K on 4/11/24. No specific details yet.
AI Summary
Enliven Therapeutics, Inc. filed an 8-K on April 11, 2024, reporting other events and financial statements. The company, formerly known as IMARA Inc. until April 19, 2016, is incorporated in Delaware and headquartered in Boulder, Colorado. This filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This 8-K filing indicates that Enliven Therapeutics has made a regulatory submission, which could contain material updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative news.
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- IMARA Inc. (company) — Former company name
- April 11, 2024 (date) — Date of report
- April 19, 2016 (date) — Date of former name change
- Boulder, Colorado (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item, but the specific details of these events are not provided in the provided text.
What is the significance of the former company name 'IMARA Inc.'?
Enliven Therapeutics, Inc. was formerly known as IMARA Inc., with a name change occurring on April 19, 2016.
Where are Enliven Therapeutics' principal executive offices located?
The principal executive offices are located at 6200 Lookout Road, Boulder, Colorado, 80301.
What is the SEC file number for Enliven Therapeutics?
The SEC file number for Enliven Therapeutics is 001-39247.
What is the IRS Employer Identification Number for Enliven Therapeutics?
The IRS Employer Identification Number for Enliven Therapeutics is 81-1523849.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-04-11 08:02:54
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
Filing Documents
- d763719d8k.htm (8-K) — 25KB
- d763719dex991.htm (EX-99.1) — 29KB
- 0001193125-24-092522.txt ( ) — 182KB
- elvn-20240411.xsd (EX-101.SCH) — 3KB
- elvn-20240411_lab.xml (EX-101.LAB) — 18KB
- elvn-20240411_pre.xml (EX-101.PRE) — 11KB
- d763719d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated April 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: April 11, 2024 By: /s/ Samuel Kintz Name: Samuel Kintz Title: President and Chief Executive Officer